Drug profile · INN
pegaspargase
ONCASPAR
pegaspargase (ONCASPAR) is a asparagine hydrolytic enzyme. Current US regulatory status: approved.
FDA: approved EMA: approved Antineoplastic and immunomodulating agents (L01) L01XX24
US status approved
Patents linked 0
Pipeline programs 5
News articles 0
Drug details — pegaspargase
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 5
- Data quality
- 0.83
Quick answer
pegaspargase (ONCASPAR) is a asparagine hydrolytic enzyme. Current US regulatory status: approved.
Key facts
INN pegaspargase
Brand ONCASPAR
Mechanism Asparagine hydrolytic enzyme
Target Asparagine
Therapeutic class Antineoplastic and immunomodulating agents (L01)
Formulation VIAL
ATC code L01XX24
Mechanism of action
Asparagine hydrolytic enzyme
Primary target: Asparagine
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is pegaspargase?
pegaspargase (ONCASPAR) is a asparagine hydrolytic enzyme. Current US regulatory status: approved.
What is the brand name for pegaspargase?
ONCASPAR is a marketed brand name for pegaspargase. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pegaspargase?
pegaspargase has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.